Finding the silent killer -- a biomarker test for atherosclerosis

Furring of the arteries, atherosclerosis, is a leading cause of death across the world. Atherosclerosis leads to peripheral arterial disease, coronary heart disease, stroke and heart attacks. However, atherosclerosis is a sneaky killer - most people do not realize they have it until they have cardiovascular disease (CV). New research published in BioMed Central's open access journal BMC Medical Genomics has identified a set of biomarkers which can be used to test for early stage atherosclerosis.

Researchers from the University of Virginia compared biomarkers isolated from monocytes (a type of ) in blood of patients with a family history of high cholesterol levels (familial ) to healthy controls. 363 genes were found to be differentially regulated (turned up or down) between the two groups. Familial hypercholesterolemia is a well-known genetic disease caused by a mutation in the which causes early onset atherosclerosis. People with two copies of the mutated LDL receptor (homozygous) have an even higher risk of atherosclerosis than those with one mutated and one normal copy (heterozygous).

Dr Feng Cheng and the team were able to reduce this initial set to 56 genes by focusing on genes directly involved in inflammation, lipid, carbohydrate and protein metabolism, and genes known to be responsible for the maintenance of blood cells. Genome-wide expression profiling, gene functional inference and multivariate statistical techniques were further used to 'fine tune' the test. This 'prediction array' was able to spot the people with high cholesterol, separating the patients with familial hypercholesterolemia from the control group.

Dr Jae Lee, who led the study, explained "By splitting our 56 genes into three sets, and using the COXEN algorithm, which was originally developed to identify genes involved in cancer with potentially diagnostic or therapeutic properties, we found that we could further refine our test and separate out the very high risk group." Dr Ellen Keeley continued, "This biomarker test, which only requires a blood sample, could be further developed to predict the risk of silent atherosclerosis in clinical practice."

More information: www.biomedcentral.com/bmcmedgenomics/

add to favorites email to friend print save as pdf

Related Stories

New atherosclerosis vaccine gives promising results

May 06, 2010

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defence's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis. ...

Genes that protect against atherosclerosis identified

Mar 14, 2008

One way of combating atherosclerosis is to reduce levels of “bad cholesterol” in the blood. Scientists at the Swedish medical university Karolinska Institutet have now identified the genes that bring about this beneficial ...

New potential atherosclerosis risk marker discovered

Apr 11, 2011

How your carotid artery moves can reveal your risk of a future heart attack, and it is now possible to study this vessel aspect in more detail thanks to a new technique which could eventually be used to identify patients ...

Recommended for you

Protein in plasma may one day change transfusions

2 hours ago

In injured mice, the naturally occurring protein fibronectin is instrumental in stopping bleeding but interestingly also at preventing life-threatening blood clots – according to new research published ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

dogbert
1 / 5 (5) Jan 13, 2012
New research published in BioMed Central's open access journal BMC Medical Genomics has identified a set of biomarkers which can be used to test for early stage atherosclerosis.


It would be good if we were to develop a blood test which could identify atherosclerosis at early stage, but the article describes an ability to identify patients with familial hypercholesterolemia. This is probably a useful test for patients in the subgroup (family history of familial hypercholesterolemia), but is not a general test for atherosclerosis.